April 3 (Reuters) - KKR has abandoned a private

equity consortium discussing a takeover of Gerresheimer AG

, Bloomberg News reported on Thursday, citing people

familiar with the matter.

Warburg Pincus, which was also a part of the consortium, is

still working to see if it can reach a deal, the report said.

Earlier this month, Reuters reported that a consortium

including KKR and Warburg Pincus had submitted a non-binding bid

for Gerresheimer.

Gerresheimer, which makes pens used to inject weight-loss

drugs such as Novo Nordisk's Wegovy, has a market

capitalization of about 2.22 billion euros, according to LSEG

data.

The consortium had submitted a bid at about 90 euros a

share, which would value the company at nearly 3.1 billion euros

($3.42 billion).

Gerresheimer and Warburg Pincus declined to comment while

KKR did not immediately respond to Reuters' requests for

comment.

In February, the German company said it was in early-stage

discussions with private equity investors over a potential sale

of the company.

Gerresheimer said at that time that the interest was

informal and on a non-binding basis.

($1 = 0.9065 euros)